Skip to main content

Table 1 Descriptive statistics of the total group of patients who underwent RRSO (n = 471)

From: The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review

  Number Percentage Range
Age (median, year) 48 % 33–78
Mutations    
-BRCA1 288 61.1  
-BRCA2 126 26.8  
-BRCA1 and BRCA2 2 0.4  
-HBOC 55 11.7  
CA-125 preoperative (n) 466   
-median (U/ml) 14.0   4.0–93.0
-elevated CA125 (>35 U/ml) (n) 10 2.1  
Surgical technique (n) 471   
-laparoscopy 430 91.3  
-laparotomy 37 7.9  
-vaginal 3 0.6  
-combined with supravaginal uterus extirpation 1 0.2  
Documented complications (n) 444 94.3  
-no complications during surgery and/or postoperatively 416 93.7  
-complications 28 5.9  
 -converted to laparotomy because of adhesions 10   
 -hematoma 10   
 -iatrogenic injury (intestine/ureter) 3   
 -incomplete removal of the ovaries 1   
 -not possible to remove ovaries because of adhesions 1   
 -other 3   
Menopausal status (n) 447   
-postmenopausal 187 41.8  
 -because of hormonal breast cancer treatment 32 17.1  
 -because of previous ovariectomy 8 4.3  
-premenopausal 241 53.9  
-perimenopausal 19 4.3  
 -because of hormonal breast cancer treatment 10 52.6  
HRT in premenopausal women (n) 217   
 -postoperative usage of HRT 97 45.3  
Follow up (median, mo) (n = 375) 55.8   0.6–169.0
-deceased in FU 19 5.1  
 -age (median, year) 55.5   43.1–72.0
-development of breast cancer in FU 57 12.1  
-development of PPC in FU 1 0.2  
-development of other malignancy 22 4.7  
Previous breast cancer (n) 195 41.4  
-age first breast cancer (median, year) 41.0   24.7–64.0
Cytology    
PWC sample not available 191 40.6  
PWC sample available 280 59.4  
-PWC analyzable 257 91.8  
 -PWC malignant 4 1.6  
 -PWC atypical 1 0.4  
Ascites sample reported 21 4.5  
-Ascites sample available for analysis 13 61.9  
 -ascites malignant 0 0  
 -ascites atypical 0 0  
Histology RRSO specimen    
Ovarian (n) 469   
-benign 399 85.1  
-primary serous adenocarcinoma 4 0.9  
-granulosa cell tumor 1 0.2  
-borderline tumor 1 0.2  
-stromal hyperplasia 2 0.4  
-mature cystic teratoma (benign) 4 0.9  
-cyst (serous/mucinous/simple/endometriosis/Theca lutein/corpus luteum) 43 9.2  
-cystadenoma/cystadenofibroma 15 3.2  
Fallopian tube (n) 470   
-benign 433 92.1  
-adenocarcinoma 5 0.6  
-serous large cell carcinoma 1 0.2  
-benign mesothelial hyperplasia 1 0.2  
-epithelial dysplasia 1 0.2  
-cystadenoma/cystadenofibroma 9 1.9  
-endometriosis 7 1.5  
-endosalpingiosis 13 2.8